Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Sclerosteosis is an autosomal recessive sclerosing bone dysplasia characterized by progressive skeletal overgrowth. The majority of affected individuals have been reported in the Afrikaner population of South Africa, where a high incidence of the disorder occurs as a result of a founder effect. Homozygosity mapping in Afrikaner families along with analysis of historical recombinants localized sclerosteosis to an interval of approximately 2 cM between the loci D17S1787 and D17S930 on chromosome 17q12-q21. Here we report two independent mutations in a novel gene, termed "SOST." Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas an unrelated affected person of Senegalese origin carries a splicing mutation within the single intron of the gene. The SOST gene encodes a protein that shares similarity with a class of cystine knot-containing factors including dan, cerberus, gremlin, prdc, and caronte. The specific and progressive effect on bone formation observed in individuals affected with sclerosteosis, along with the data presented in this study, together suggest that the SOST gene encodes an important new regulator of bone homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in genes that have highly enriched expression in osteocytes cause rare bone and mineral disorders.”
From Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease (2021) · cites this paper as [17]
Citations
Cites
Bone: Formation by Autoinduction
Urist, M. R. (1965) · Science · doi:10.1126/science.150.3698.893 · Cited by 5,546 · cited 1×
“Although this family of morpho-gens was originally identified on the basis of bone-in-ducing activity (Urist 1965), a number of these factors have been shown to be critical for very early stages of embryogenesis and fetal development.”
Prediction of complete gene structures in human genomic DNA
Burge, C., & Karlin, S. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0951 · Cited by 4,228 · cited 8×
“The novel variant gene (designated “P50gsc3”) predicted by GENSCAN was located between markers D17S951 and D17S1860 (fig.”
InfluentialA comprehensive genetic map of the human genome based on 5,264 microsatellites
Dib, C., Fauré, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Kazan, J., Seboun, E., et al. (1996) · Nature · doi:10.1038/380152a0 · Cited by 2,928 · cited 3×
“D17S1793, D17S1789, D17S951, and D17S1860 within the critical region bounded by D17S1787 and D17S930, an interval of ∼ 2 cM (Dib et al. 1996) on the cytogenetic border between the chromosomal bands 17q12–q21.”
Bone morphogenetic proteins: multifunctional regulators of vertebrate development.
Hogan, B. L. (1996) · Genes & Development · doi:10.1101/gad.10.13.1580 · Cited by 1,962
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · cited 1×
“Currently there is no effective treatment for the restoration of normal bone mass in individuals with pathologically low skeletal density, and there is a large unmet need for therapy that can increase bone deposition in osteoporosis (Rodan and Martin 2000).”
BackgroundEasy calculations of lod scores and genetic risks on small computers.
Lathrop, M. G., & Lalouel, J.-M. (1984) · Europe PMC (PubMed Central) · Cited by 1,526
Faster sequential genetic linkage computations.
Cottingham, R. W., Idury, R. M., & Schäffer, A. A. (1993) · Europe PMC (PubMed Central) · Cited by 1,364
Nonsense-mediated mRNA decayin health and disease
Frischmeyer, P. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.10.1893 · Cited by 992 · cited 1×
“The relatively low levels of mutant transcripts observed could be the result of nonsense-mediated mRNA decay, as the inclusion of intronic sequence introduced an in-frame nonsense codon (Frischmeyer and Dietz 1999; Hentze and Kulozik 1999).”
BackgroundHomozygosity Mapping: A Way to Map Human Recessive Traits with the DNA of Inbred Children
Lander, E. S., & Botstein, D. (1987) · Science · doi:10.1126/science.2884728 · Cited by 875
FORMATION AND FUNCTION OF SPEMANN'S ORGANIZER
Harland, R., & Gerhart, J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.611 · Cited by 839 · cited 1×
“In addition, the requirement for the coordinated expression of negative regulators of BMP activity, such as noggin and chordin, as well as members of the dan family, has been well described (Harland and Gerhart 1997; Sasai and De Robertis 1997; Hsu et al. 1998).”
Background
Research works printed but not linked: 3
- Gardner J (1999) Profound childhood deafness in South Africa: a clinical and molecular genetic approach. Ph.D. thesis, University of Cape Town, Cape Town
- Hausen, 1967, Sklerosteose, Vol. 6, 351
- Peitruschka, 1958, Weitere Mitteilungen über die Marmorknochenkrankheit (Albers-Schonbergsche Krankheit) nebst Bemerkungen zur Differentialdiagnose, Klin Monatbl, 132, 509
Cited by
Items 701–800 of 1,000
BMP signalling in colorectal cancer: losing the yin to WNTs yang
Clarkson, E., & Lewis, A. (2025) · The Journal of Pathology · doi:10.1002/path.6428 · Cited by 7
“Sclerostin has some homology to the DAN family of BMP antagonists and more distantly to Noggin [90].”
Analytic approach to explore dynamical osteoporotic bone turnover
Javed, S., Younas, M., Bhatti, M. Y., Sohail, A., & Sattar, A. (2019) · Advances in Difference Equations · doi:10.1186/s13662-019-1986-7 · Cited by 8
New therapeutic options for bone diseases
Kocijan, R., Haschka, J., Feurstein, J., & Zwerina, J. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-020-00810-w · Cited by 7
CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system
Laster, D. J., Akel, N. S., Hendrixson, J. A., James, A., Crawford, J. A., Fu, Q., Berryhill, S. B., Thostenson, J. D., Nookaew, I., O’Brien, C. A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107428 · Cited by 7
Tsukamoto, S., Kuratani, M., Tanaka, S., Jimi, E., Oda, H., & Katagiri, T. (2023) · Development · doi:10.1242/dev.201734 · Cited by 8
Samiei, M., Janjić, K., Cvikl, B., Moritz, A., & Agis, H. (2019) · F1000Research · doi:10.12688/f1000research.17801.1 · Cited by 8
Looking for new anabolic treatment from rare diseases of bone formation
Rossi, M., Battafarano, G., Martino, V. D., Scillitani, A., Minisola, S., & Fattore, A. D. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0285 · Cited by 7
“TGFβ1 stimulates osteoblast differentiation in the early stages, and inhibits the later phase of proliferation and mineralisation that are more susceptible to BMP signalling.”
BackgroundInfluentialMcDonald, G. L. K., Wang, M., Hammond, C. L., & Bergen, D. J. M. (2021) · Biomolecules · doi:10.3390/biom11020277 · Cited by 7
“Studies of rare bone diseases associated with HBM and subsequent detailed functional characterisation of identified associated genes, such as the Wnt regulator SOST, have underpinned the development of the new OP therapeutic Romozsumab, an antibody that blocks SOST function leading to bone anabolism [56,57].”
BackgroundBone morphogenetic protein receptors and their nuclear effectors in bone formation
Korchynskyi, O., van Bezooijen, R. L., Löwik, C. W. G. M., & ten Dijke, P. (2004) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7857-9_2 · Cited by 14
Diamond, K. M., Burtner, A. E., Siddiqui, D., Alvarado, K., Leake, S., Rolfe, S. M., Zhang, C., Kwon, R. Y., & Maga, A. M. (2023) · Journal of Anatomy · doi:10.1111/joa.13847 · Cited by 7
Tholpady, S. S., Dodd, Z. H., Havlik, R. J., & Fulkerson, D. H. (2012) · World Neurosurgery · doi:10.1016/j.wneu.2012.11.061 · Cited by 7
Kuczera, P., Adamczak, M., & Więcek, A. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0392-6 · Cited by 7
“Deletion, or attenuation of SOST gene at the transcriptional level lead to the development of sclerostosis, or van Buchem’s disease – both of these morbidities lead to the increased bone mass [5, 6].”
BackgroundAlterations of BMP signaling pathway(s) in skeletal diseases
Seemann, P., Mundlos, S., & Lehmann, K. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8552-1_8 · Cited by 7
Sclerostin: From bedside to bench, and back to bedside
Robling, A. G., Drake, M. T., & Papapoulos, S. E. (2017) · Bone · doi:10.1016/j.bone.2017.01.019 · Cited by 7
Signaling in Osteoblast Differentiation
Hayashi, M., Ono, T., & Nakashima, T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11182-1 · Cited by 7
Ozawa, Y., Takegami, Y., Osawa, Y., Asamoto, T., Tanaka, S., & Imagama, S. (2024) · Bone · doi:10.1016/j.bone.2024.117030 · Cited by 7
Henriksen, K., Thudium, C. S., Christiansen, C., & Karsdal, M. A. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1045415 · Cited by 7
“There are however reports of sclerostin expression in other tissues as well [22].”
BackgroundManagement of trigeminal neuralgia in sclerosteosis
de Andrade, E. M., Beer‐Furlan, A., Duarte, K. P., Fonoff, E. T., & Teixeira, M. J. (2013) · Surgical Neurology International · doi:10.4103/2152-7806.121644 · Cited by 6
“It is caused by mutations in SOST gene encoding sclerostin protein, an osteocyte-specific secreted protein that is likely involved in the suppression of bone formation.[2,6,13,27,30]”
BackgroundHendrickx, G., Boudin, E., Steenackers, E., Collet, C., Mortier, G. R., Geneviève, D., & Hul, W. V. (2022) · Bone · doi:10.1016/j.bone.2022.116633 · Cited by 6
Han, R.-Y., Tan, R., Xu, L., Lin, J.-Y., Li, T., Su, H.-W., Li, P., Liu, P., Lan, H.-Y., & Wang, L. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103762 · Cited by 7
“Although Sost is typically considered a protein specific to osteo-cytes, its presence has been detected across various human organs including the kidneys, liver, heart, and brain [6].”
RetractedIdentification of receptor-type protein tyrosine phosphatase μ as a new marker for osteocytes
de Rooij, K. E., van der Velde, M., de Wilt, E., Deckers, M. M. L., Bezemer, M., Waarsing, J. H., Que, I., Chan, A. B., Kaijzel, E. L., & Löwik, C. W. G. M. (2015) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1319-1 · Cited by 6
“Sclerostin, the protein of the Sost gene, is an osteocyte-specific inhibitor of bone formation (van Bezooijen et al. 2004), which when absent results in the sclerosing bone disorder sclerosteosis 1 3 (Balemans et al. 2001; Brunkow et al. 2001).”
BackgroundCzajkowska, M., Plinta, R., Owczarek, A. J., Olszanecka‐Glinianowicz, M., & Skrzypulec‐Plinta, V. (2019) · Ginekologia Polska · doi:10.5603/gp.2019.0064 · Cited by 6
Deletion of the sodium/hydrogen exchanger 6 causes low bone volume in adult mice
Schnyder, D., Albano, G. D., Kucharczyk, P., Dolder, S., Siegrist, M., Anderegg, M. A., Pathare, G., Hofstetter, W., Baron, R., & Fuster, D. G. (2021) · Bone · doi:10.1016/j.bone.2021.116178 · Cited by 6
Whyte, M. P. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch93 · Cited by 6
A new familial sclerosing bone dysplasia
Chouery, É., Pangrazio, A., Frattini, A., VILLA, A. M., Wesenbeeck, L. V., Piters, E., Hul, W. V., Coxon, F. P., Schouten, T., Helfrich, M., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090733 · Cited by 7
“In addition, no mutations were found in the SOST gene or its regulatory element, known to be responsible for sclerosteosis((16,17)) and van Buchem disease,((18,19)) respectively.”
BackgroundExploiting new targets for old bones
Rosen, C. J. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.91 · Cited by 6
“Sclerosteosis, another genetic disorder associated with high bone mass, results from loss-of-function mutations in the SOST gene.((8)) This disease is also characterized by increased bone formation but impaired osteoclastic activity.”
BackgroundSclerostin antibodies as novel anabolic therapy for osteoporosis
Mamedova, E., Grebennikova, T. A., Belaya, Z. E., & Rozhinskaya, L. Y. (2019) · Osteoporosis and Bone Diseases · doi:10.14341/osteo10127 · Cited by 7
A novel biallelic splice‐site variant in the LRP4 gene causes sclerosteosis 2
Bukowska‐Olech, E., Sowińska‐Seidler, A., Szczałuba, K., & Jamsheer, A. (2020) · Birth Defects Research · doi:10.1002/bdr2.1676 · Cited by 7
Chandra, A., Rosenzweig, A. B., & Pignolo, R. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-72228-3_1 · Cited by 7
Rubin, J. E., & Rubin, C. T. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0608 · Cited by 7
WNT Signaling in Skeletal Homeostasis and Diseases
Gori, F., & Baron, R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00018-2 · Cited by 6
Yeon, S., Seto, S. W., Bhuyan, D. J., Chang, D., Li, C. G., & Low¹, M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01377-w · Cited by 5
“Sclerostin is a 213–amino acid secreted glycoprotein encoded by the SOST gene and characterised by a modular three-domain architecture [17].”
Bone matrix proteins: regulators of skeletal remodeling and repair
Chen, T., Chu, P., Guo, J., & Shen, B. (2026) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-026-01708-0 · Cited by 5
Chronic Kidney Disease–Mineral and Bone Disorders
Hruska, K. A., Williams, M. J., & Sugatani, T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00035-8 · Cited by 8
A Novel Mutation in a Gene Causes Sclerosteosis in a Family of Mediterranean Origin
Ekhzaimy, A. A., Alyusuf, E. Y., Alswailem, M. M., & Alzahrani, A. S. (2022) · Medicina · doi:10.3390/medicina58020202 · Cited by 5
“, 2001 [13] 6: Yes, 2: NK21: No South Africa NK c.”
BackgroundRole of sclerostin in mastocytosis bone disease
Szudy‐Szczyrek, A., Mlak, R., Pigoń-Zając, D., Krupski, W., Mazurek, M., Tomczak, A., Chromik, K., Górska, A., Koźlik, P., Juda, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-83851-0 · Cited by 5
“Loss-of-function mutations of the gene cause a condition called sclerosteosis, while insufficient expression is responsible for the pathogenesis of van Buchem disease 26–28 .”
Mughal, Z. (2009) · Endocrine development · doi:10.1159/000223696 · Cited by 5
Sclerostin Inhibition in the Treatment of Osteoporosis
Baron, R., Gori, F., & Leder, B. Z. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_19 · Cited by 6
Chapter 88. Sclerosing Bone Disorders
Whyte, M. P. (2008) · Wiley eBooks · doi:10.1002/9780470623992.ch88 · Cited by 5
Anatomy and Physiology of Skeletal Tissue: The Bone Cells
Brunetti, G., Colaianni, G., Colucci, S. C., & Grano, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-75110-8_1 · Cited by 7
The Shisa3 knockout mouse exhibits normal bone phenotype
Murakami, K., Zhifeng, H., Suzuki, T., Kobayashi, Y., & Nakamura, Y. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01014-y · Cited by 8
Zhou, S., Ge, Y., Li, Y., Bao, Z., Chen, Y., Teng, H., & Jiang, Q. Y. (2017) · PubMed · Cited by 5
Koromani, F., Alonso, N., Alves, I., Brandi, M. L., Foessl, I., Formosa, M. M., Frenkel‐Morgenstern, M., Karasik, D., Kolev, M., Mäkitie, O., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.709815 · Cited by 5
Reflecting on Some Discoveries of 40 Years and Their Outcomes
Martin, T. J. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3282 · Cited by 5
“Inactivating mutations were also found in this gene in a group of affected Afrikaans subjects.((55)) There were no mutations found in SOST in van Buchem disease—instead they discovered a 52-kb deletion in the distal region.”
BackgroundRecent progress in the molecular genetics of sclerosing bone dysplasias
Hul, W. V. (2003) · Fetal and Pediatric Pathology · doi:10.1080/15227950307696 · Cited by 6
Disorders of Bone Density, Volume, and Mineralization
Descartes, M. D., & Sillence, D. O. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00164-6 · Cited by 5
Saag, K. G., Curtis, J. R., & Reid, I. R. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4000 · Cited by 5
Editorial: Recent Advances in the Genetics of Osteoporosis
Tobias, J. H., & Karasik, D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.656298 · Cited by 5
“Given the successful translation from identification of the genetic basis of sclerosteosis to new therapy in the case of Romosozumab (1, 2), further genetic dissection of HBM cases may provide additional benefits for human health.”
BackgroundStelmaszek, S., Tarasiuk, E., Knapp, M., Kazimierczyk, R., & Lisowska, A. (2025) · Advances in Medical Sciences · doi:10.1016/j.advms.2025.10.003 · Cited by 4
Integrative modeling of drug therapy and the bone turnover
Javed, S., Sohail, A., & Nutini, A. (2018) · Clinical Biomechanics · doi:10.1016/j.clinbiomech.2018.10.019 · Cited by 5
Rare and Common Variants in GALNT3 May Affect Bone Mass Independently of Phosphate Metabolism
Hassan, N., Gregson, C. L., Tang, H., van der Kamp, M. W., Leo, P., McInerney-Leo, A. M., Zheng, J., Brandi, M. L., TANG, J. C. Y., Fraser, W. D., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4795 · Cited by 4
“This agent, which consists of an anti-sclerostin antibody, was developed after the discovery that mutations in and around SOST,(5,6) the gene encoding sclerostin, underlie the rare diseases sclerosteosis(5) and van Buchem’s disease(7); common variants at this locus are also associated with bone mineral density (BMD) (…”
BackgroundJohnson, M. L. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2459 · Cited by 5
“Initially we had the identification of mutations in LRP5 that gave rise to both low((1)) and high bone mass (HBM),((2,3)) followed shortly thereafter by the identification of mutations causal for sclerosteosis((4,5)) and van Buchem disease((6,7)) that identified the SOST gene and its protein product sclerostin as impo…”
BackgroundEmbryonic Skeletogenesis and Craniofacial Development
Mishina, Y. M., & Kamiya, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-47507-3_3 · Cited by 4
Sclerostin, bone morphogenetic protein, Wnt and the lung: a potential role beyond bone metabolism?
Biasin, V., & Obermayer-Pietsch, B. M. (2018) · Journal of Laboratory and Precision Medicine · doi:10.21037/jlpm.2018.11.05 · Cited by 4
Mert, M., Dursun, B., Yağcı, B., KARDEŞLER, A. Ç., Şenol, H., & Demir, S. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02336-6 · Cited by 4
WNT signaling in skeletal homeostasis and diseases
Gori, F., & Baron, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00012-5 · Cited by 5
Hendrickx, G., Boudin, E., Mateiu, L. M., Yorgan, T. A., Steenackers, E., Kneissel, M., Krämer, I., Mortier, G. R., Schinke, T., & Hul, W. V. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01158-0 · Cited by 4
The Role of Non-collagenous Proteins and Other Matrix Molecules in Vertebrate Mineralization
Shapiro, I. M., & Landis, W. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-34304-9_8 · Cited by 7
Johnson, M. L. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00013-6 · Cited by 5
Bone morphogenetic protein signaling is fine-tuned on multiple levels
Sieber, C., Schwaerzer, G. K., & Knaus, P. I. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8552-1_6 · Cited by 7
Mutations in sFRP1 or sFRP4 are not a common cause of craniotubular hyperostosis
Boudin, E., Piters, E., Fijałkowski, I., Stevenheydens, G., Steenackers, E., Kuismin, O., Moilanen, J. S., Mortier, G. R., & Hul, W. V. (2012) · Bone · doi:10.1016/j.bone.2012.09.034 · Cited by 4
“In 2001, we and others showed that deficiency of sclerostin encoded by the SOST gene causes the autosomal recessive disorders sclerosteosis and Van Buchem disease [1–3].”
BackgroundSingle gene mutations and variations affecting bone turnover and strength: a selective 2006 update
Ferrari, S. (2006) · BoneKEy-Osteovision · doi:10.1138/20060240 · Cited by 5
“In both disorders, the responsible mutations lie within or closely downstream of the SOST gene (24;25) that codes for sclerostin, a protein that is highly expessed in osteocytes (26).”
BackgroundSecreted Wnt Inhibitors or Modulators
Bovolenta, P., Gorny, A., Esteve, P., & Steinbeißer, H. (2014) · Wiley eBooks · doi:10.1002/9781118444122.ch13 · Cited by 4
Production and Characterization of Monoclonal Antibodies to Human Sclerostin
Craig, T. A., Sommer, S. L., Beito, T. G., & Kumar, R. (2009) · Hybridoma · doi:10.1089/hyb.2009.0036 · Cited by 4
“…mutations, either in the promoter or coding sequence of the gene, are present in van Buchem disease or sclerosteosis, and result in a general progressive overgrowth and sclerosis of the skeleton (8–11) due to reduction of full-length scl expression or expression of mutant scl with reduced activity.”
Oxygen Sensing in Osteocytes: From Physiology to Age-related Osteoporosis
Janeczko, K., & Agoro, R. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00920-7 · Cited by 3
“Osteocytes produce sclerostin (SOST), which binds to low-density lipoprotein receptor-related protein (Lrp)5/6, and neutralizes the anabolic Wnt/beta-catenin pathway, [29, 30] thus negatively regulating bone formation and driving osteoporosis.”
Increased serum sclerostin in postoperative biliary atresia
Honsawek, S., Udomsinprasert, W., Chaiwatanarat, T., Vejchapipat, P., Chongsrisawat, V., & Poovorawan, Y. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.030 · Cited by 3
“Genetic defects that cause a lack of sclerostin expression and therefore result in significantly increased bone mass occur in sclerosteosis and van Buchem disease; whereas high sclerostin expression leads to low bone mass in mice [11–13].”
BackgroundBasic and Clinical Scientists Working Together—Do We Make the Best of Both Worlds?
Lems, W. F., Anastasilakis, A. D., Andreasen, C. M., Paccou, J., Rolvien, T., Tencerová, M., Tuckermann, J. P., Yavropoulou, M. P., & Søe, K. (2025) · Calcified Tissue International · doi:10.1007/s00223-025-01347-z · Cited by 3
Wang, R., Yu, Z., Yang, G., Xu, Z., Liu, Y., Zhao, W., Wang, H., Mei, H., & Zhu, G. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03759-4 · Cited by 3
“For example, autosomal recessive inactivating mutations in SOST , which encodes the Wnt-antagonist sclerostin, result in the high bone mass disorder sclerosteosis type 1 (OMIM: 269,500) [21].”
Katagiri, T., Tsukamoto, S., Osawa, K., & Kokabu, S. (2014) · Mechanical engineering series · doi:10.1007/978-3-319-13266-2_1 · Cited by 3
Sclerosing bone disorders: a lot of knowns but still some unknowns
Hul, W. V. (2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.97 · Cited by 3
Bodine, P. V. N. (2007) · BoneKEy-Osteovision · doi:10.1138/20070255 · Cited by 5
“SOST was identified as the gene that is inactivated in the bone dysplasia sclerosteosis, a HBM disease that predominantly affects the Afrikaner population of South Africa (44).”
BackgroundOsteopetrosis: from Animal Models to Human Conditions
Perdu, B., Hul, W. V., & Wesenbeeck, L. V. (2008) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-008-9021-7 · Cited by 3
“Furthermore, loss of function mutations underlying Van Buchem disease and sclerosteosis were found in the SOST gene encoding sclerostin, which turned out to be an inhibitor of wnt signalling [12–15].”
BackgroundDelgado‐Calle, J., Pérez-Campo, F. M., & Riancho, J. (2014) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2014000400006 · Cited by 3
Hereditary Disorders of the Skeleton
Whyte, M. P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00068-8 · Cited by 4
Ni, X., Zhang, Q., Li, X., Pang, Q., Gong, Y., Wang, O., Li, M., Xing, X., Jiang, Y., & Xia, W. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab579 · Cited by 3
Milovanova, L. Y., Beketov, V. D., Milovanova, S. Y., Taranova, M. V., Filippova, A. A., & Pasechnik, A. I. (2021) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2021-99-4-245-258 · Cited by 3
Lee, S. M., Meyer, M. B., Benkusky, N. A., & Pike, J. W. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106335 · Cited by 3
Bienvenu, J. G., Chouinard, L., Felx, M., Boyce, R. W., & Monticello, T. M. (2023) · Bone · doi:10.1016/j.bone.2023.116985 · Cited by 3
Pereira, R. C., Noche, K. J., Gales, B., Chen, Z., Salusky, I. B., & Albrecht, L. V. (2024) · Children · doi:10.3390/children11070820 · Cited by 3
The new frontier of bone formation: a breakthrough in postmenopausal osteoporosis?
Ruiz, C., Abril, N., Tarín, J. J., García‐Pérez, M. Á., & Cano, A. (2009) · Climacteric · doi:10.1080/13697130902736939 · Cited by 3
BMP and BMP Regulation: Structure and Function
Nolan, K., & Thompson, T. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-47507-3_4 · Cited by 3
López, J. M., Balemans, W., Piters, E., Hul, W. V., & González, G., V (2008) · Bone · doi:10.1016/j.bone.2008.04.011 · Cited by 3
“At present, ten heterozygous missense mutations in the first out of four β-propeller domains of the extracellular portion of LRP5 have been reported in AD types [3–10], while six loss-of-function SOST mutations have been found in AR craniotubular hyperostosis [11–15].”
BackgroundHulley, P. A., Russell, R. G. G., & Croucher, P. I. (2006) · Elsevier eBooks · doi:10.1016/b9-78-012088-5/62650-0078 · Cited by 4
Rosenzweig, A. B., & Pignolo, R. J. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-467-8_1 · Cited by 3
Control of Bone Homeostasis by the Wnt Inhibitor Sclerostin
McGee‐Lawrence, M. E., & Hamrick, M. W. (2016) · Current Molecular Biology Reports · doi:10.1007/s40610-016-0040-8 · Cited by 3
Introduction to Genetics of Skeletal and Mineral Metabolic Diseases
Newey, P. J., Gorvin, C. M., Whyte, M. P., & Thakker, R. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804182-6.00001-0 · Cited by 5
Wnt Signaling and Genetic Bone Diseases
Lu, Y., & Han, J. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81070 · Cited by 3
Wnt Signaling in Bone Development
Bodine, P. V. N. (2010) · Springer eBooks · doi:10.1007/978-1-84882-822-3_9 · Cited by 3
On platelet-rich plasma in reconstructive dental implant surgery.
Thor, A. L. I. (2006) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 5
Lessons from Sclerosing Bone Dysplasias
Hul, W. V. (2007) · Hormone Research in Paediatrics · doi:10.1159/000110472 · Cited by 3
Bone Cells: Osteoblast/Osteoclast/Osteocyte
Rucci, N., & Teti, A. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64347-7 · Cited by 3
Lifelong genetically lowered sclerostin and risk of cardiovascular diseasePreprint
Bovijn, J., Krebs, K., Chen, C., Boxall, R., Censin, J. C., Ferreira, T. D. G. M., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/531004 · Cited by 3
Editorial: Crosstalk between bone and other cells
Charoenphandhu, N., Chanpaisaeng, K., Teerapornpuntakit, J., & Wongdee, K. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1209053 · Cited by 3
“, cartilage, heart, kidney, and liver as well (Brunkow et al., 2001; Weivoda et al., 2017).”
BackgroundEnhancing Wnt signaling lowers fracture incidence in a severe mouse model of Osteogenesis Imperfecta
Montagna, G., Lee, S., Baacke, A., Warman, M. L., & Jacobsen, C. M. (2025) · Bone · doi:10.1016/j.bone.2025.117641 · Cited by 3
Geusens, P., Hul, W. V., van den Bergh, J. P., & Lems, W. F. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2594642 · Cited by 2
“As further discussed in more detail, the disease-causing gene was localized on chromosome 17 in late 1990s [19], with the identification of the SOST (SclerOSTin) gene in 2001 by two independent groups [20,21] and of the structure of its secreted protein called sclerostin in 2009 [22].”
3 months of romosozumab: a pragmatic clinical solution
Khosla, S. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00323-7 · Cited by 2
Sclerostin deficiency sensitizes white adipocytes to thermogenic signals that induce beiging in mice
Choquette, G. M., Kim, S. P., Wilkinson, K. J., Avelar, B., Pathy, S. M., Li, Z., Wu, J. M. F., Aja, S. M., Thorek, D. L. J., Wolfgang, M. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69227-0 · Cited by 3
“The function of sclerostinhasprimarilybeenstudiedinthecontextofboneacquisition as the protein acts as a local antagonist of osteo-anabolic Wnt/ β - catenin signaling in the bone microenvironment and loss-of-function mutations in the SOST gene lead to dramatic bone overgrowth 33 – 35 .”
The pathogenesis and intersecting mechanisms of monogenic bone mass disorders
Padidela, R., Hendrickx, G., Mortier, G. R., & Mäkitie, O. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01260-x · Cited by 2
“SOST-related sclerosteosis is caused by biallelic, truncating pathogenic variants in the SOST gene, which encodes sclerostin 16 (Fig.”
Proxied therapeutic inhibition on sclerostin and atrial fibrillation risk
Qian, Y., Guan, P.-L., Hu, J., Han, M., Fang, Y., Wang, W.-L., Khederzadeh, S., Hou, Y.-P., Qiu, M.-C., Gao, J.-H., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01694-4 · Cited by 2
“SOST gene, can inhibit the Wnt pathway signaling in osteoblasts, thus reducing bone formation 9,10 .”
Oscillatory intracellular Ca2+ responses in living bone
Ishihara, Y., Sugawara, Y., Kamioka, H., Kawanabe, N., Naruse, K., & Yamashiro, T. (2014) · Journal of Oral Biosciences · doi:10.1016/j.job.2014.03.002 · Cited by 2
Metadata
- Authors
- Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P., & Mulligan, J. T.
- Affiliations
- University of Cape Town (ZA)
- University of Cagliari (IT)
- Corresponding author
- Brunkow, Mary E.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-03
- Volume
- 68
- Issue
- 3
- Pages
- 577-589
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1274471
- OpenAlex
- W2037750372
- Cited by
- 1,011
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 32 · 2023: 27 · 2022: 36 · 2021: 53 · 2020: 52 · 2019: 46 · 2018: 50 · 2017: 56 · 2016: 65 · 2015: 61 · 2014: 58 · 2013: 60 · 2012: 56
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4523 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- sclerosteosis, SOST gene, skeletal dysplasia, cystine knot proteins, bone homeostasis, skeletal overgrowth, nonsense mutation, splicing mutation, founder effect, Afrikaner population, bone formation regulation
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Bone Diseases, Chromosome Mapping, Chromosomes, Human, Pair 17, Consanguinity, Cystine, Female, Genetic Markers, Homozygote, Humans, Male, Molecular Sequence Data, Netherlands, Pedigree, Proteins, Recombination, Genetic, Sclerosis, Senegal, South Africa, Conserved Sequence, Alternative Splicing, Bone Morphogenetic Proteins, Mutation, Missense, Black People, White People, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.